Last reviewed · How we verify
NCT05163730
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
NA trial testing COVID-19/ Flu A&B Rapid Panel in COVID-19 in 2,472 participants. Completed in 11 February 2022.
11 February 2022
Quick facts
| Lead sponsor | Abbott Rapid Diagnostics Jena GmbH |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 2,472 |
| Start date | 1 November 2021 |
| Primary completion | 11 February 2022 |
| Estimated completion | 11 February 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- COVID-19/ Flu A&B Rapid Panel
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Influenza A — all drugs for Influenza A →
- Influenza Type B — all drugs for Influenza Type B →
Sponsor
Abbott Rapid Diagnostics Jena GmbH
Who can join
Eligibility, any sex, with COVID-19 or Influenza A. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed as a prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal swabs. This study is part of the performance evaluation to support the CE conformity assessment procedures.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
SARS-CoV-2 versus Influenza A Virus: Characteristics and Co-Treatments.
Wang X, Li J, Liu H, Hu X, et al · · 2023 · cited 7× · PMID 36985154 · DOI 10.3390/microorganisms11030580
Verify or expand the search:
- PubMed search for NCT05163730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Abbott Rapid Diagnostics Jena GmbH trials
Trials by the same sponsor.
- NCT04959760 — BinaxNow COVID-19 IgG Rapid Test Device and Antibody Self Test · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05163730 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abbott Rapid Diagnostics Jena GmbH
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05163730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing